February 22, 2021
Following the unprecedented health crisis and its unprecedented economic impact, the Government has put in place numerous tools to support businesses. A total budget of €600 million has been dedicated to the relocation of projects in critical sectors (health, agri-food, electronics, essential industrial inputs, etc.) via the "France Relance" call for projects.
31 winners had already been selected in November 2020. Today, Bruno Lemaire and Agnès Pannier-Runacher have presented 34 new winners representing a potential of more than 1,100 job creations and enabling nearly 3,000 others to be confirmed. The company from Besançon specialised in the bio-production of plasmids, RD-Biotech, was selected.
Read the full press release 🔽
https://bit.ly/3aoieqn
Cellura developped a new kind of bioreactor based on the principle of Earth’s precession movement. Its bladeless mixing system allows homogeneous mixing with low shear forces, by respecting specific aspect...
Learn moreThe CliniMACS Prodigy® represents the next generation in automated cell processing, offering advanced integrated solutions to streamline cell processing workflows – from cell separation through cell culture to formulation of...
Learn moreCAR-engineered NK cells represent a breakthrough in cancer immunotherapy, offering a host of advantages. These include multiple cytotoxicity mechanisms, a decreased risk of graft-versus-host disease (GVHD) in allogeneic scenarios, and...
Learn moreSince 1953, Tebubio facilitates Life Sciences research in France and throughout Europe. With over 80 team members across Europe, we provide researchers with a range of innovative solutions in many...
Learn moreIn response to the growing need for mRNA, Tebubio’s laboratories offer a mini-scale mRNA production service to quickly provide you with customised and optimised research grade sequences to be used...
Learn moreProteintech is a leading manufacturer of antibodies, immunoassays, proteins and Nanobodies. Overview of the Proteintech product range: Antibodies against 13,000+ human targets. Trial size versions available. Immunoassay kits...
Learn moreThe CliniMACS Prodigy® Tumor Reactive T (TRT) Cell Process offers a new, adaptable platform for scientists and clinicians working on tumor-infiltrating leukocyte (TIL) therapy, and can be tailored to the...
Learn moreAffinity between chimeric antigen receptor (CAR) T cells and their target have shown to be a poor predictor for T-cell function. On the contrary, cell avidity (or overall cellular binding...
Learn moreThe CliniMACS Prodigy represents the next generation in automated cell processing. This device offers advanced integrated solutions to streamline cell processing workflows – from cell separation through cell culture to...
Learn moreWe are pleased to announce that Gilson Connect solutions have been selected by Syngoi Technologies to enforce the traceability and repeatability of manual protocols. Syngoi Technologies is a biotechnology company...
Learn moreGilson is pleased to announce a new chapter of collaborating with the EFS Gene and Cell engineering unit of Bourgogne Franche Comté. The collaboration provides the EFS Development & Transfer...
Learn moreTo address the variety of Treg cell applications, Miltenyi Biotec provides a broad range of tools for clinical use.
Learn moreCREAPHARM BIOSERVICES has recently invested in -80°C nitrogen tanks to provide Biotechs and Research key players with a new solution to meet the challenges of ultra-low temperature storage.
Learn moreToday, Gene and Cell therapies are booming. However, due to the lack of solutions allowing rapid & continuous monitoring throughout the bioproduction process, Biotech’ companies are working “almost blind”. They...
Learn moreThe Videodrop makes it possible to measure the size and concentration of biological nanoparticles like lentivirus, adenovirus or retrovirus
Learn moreGEN recently interviewed our Business Development Director, Dr. Natalia Elizalde, with whom they spoke about improving the production of lentiviral vectors, vectors that VIVEbiotech develops and manufactures.
Learn moreCytiva, a global life sciences leader, and Nucleus Biologics, LLC, The Cell Performance Company™, have signed a collaboration agreement on custom media formulation and fulfillment solutions for the cell and...
Learn morePharmaBoardroom, a leading British media specialized in the health sector, has published an article in which it highlights VIVEbiotech as one of the ten Spanish biotechs to follow in 2022.
Learn moreThe Analytical Scientist interviewed Rakel Lopez de Maturana, VIVEbiotech´s Qualified Person & Regulatory Affairs Director.
Learn moreThe CEO of VIVEbiotech, Dr. Gurutz Linazasoro, is part of the prestigious The Medicine Maker Power List.
Learn moreThe Business Development Director of VIVEbiotech Dr. Natalia Elizalde was interviewed by The Medicine Maker on the challenges of lentiviral vector manufacture/use.
Learn moreVectorBuilder Inc., a global leader in vector design, optimization and GMP manufacturing, and Landau Biotechnology Co., a world leader in developing nonhuman primate (NHP) models for clinical research applications, have...
Learn moreVectorBuilder – a global leader in vector design, optimization, and GMP manufacturing – has formed a worldwide strategic partnership with Univercells Technologies, a provider of novel biomanufacturing technologies for flexible...
Learn moreMedXCell Science SA: MedXCell Science SA was co-founded in 2018 by the University Hospital of Montpellier (CHU of Montpellier) in France and the Swiss company MedXCell SA. It was the...
Learn moreA prolific period for researchers, confinement has allowed the Etablissement Français du Sang teams to generate and mature many ideas from pre-existing research. In Besançon, Marina Deschamps and Christophe Ferrand...
Learn more